

## Extrahepatic Portal Venous Obstruction due to a Giant Hepatic Hemangioma Associated with Kasabach-Merritt Syndrome

Aya Tani<sup>1</sup>, Hiroshi Yoshida<sup>2</sup>, Yasuhiro Mamada<sup>1</sup>,  
Nobuhiko Tanai<sup>1</sup>, Yoichi Kawano<sup>1</sup> and Eiji Uchida<sup>1</sup>

<sup>1</sup>Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School

<sup>2</sup>Department of Surgery, Nippon Medical School Tama Nagayama Hospital

### Abstract

We describe a patient with extrahepatic portal venous obstruction due to a giant hepatic hemangioma associated with Kasabach-Merritt syndrome. A 67-year-old woman presented with upper abdominal distension and appetite loss. The medical history was not relevant to the current disorder. Initial laboratory tests revealed the following: serum platelet count,  $9.9 \times 10^4/\mu\text{L}$ ; serum fibrinogen degradation products,  $12 \mu\text{g/mL}$ ; prothrombin time, 1.26; and serum fibrinogen,  $111 \text{ mg/dL}$ . Computed tomography demonstrated homogenous low-density areas, 15 cm in diameter, in the left lobe of the liver. Common hepatic arteriography revealed a hypervascular tumor with pooling of contrast medium in the delayed phase. The portal venous phase of supramesenteric arteriography revealed obstruction and cavernous transformation of the portal vein. We diagnosed extrahepatic portal venous obstruction due to a giant hepatic hemangioma associated with Kasabach-Merritt syndrome. Laparotomy was performed, and the liver was found to be markedly enlarged. After mobilization of the left lobe, left hepatectomy was performed with intermittent clamping. After resection, Doppler ultrasonography revealed recovery of the portal venous flow. The cavernous transformation shrank. Pathologic examination of the surgical specimen confirmed the presence of a giant benign hepatic cavernous hemangioma. The patient was discharged 16 days after operation. Laboratory data and complications improved after 2 months.

(J Nippon Med Sch 2010; 77: 269-272)

**Key words:** hemangioma, Kasabach-Merritt syndrome, giant, portal venous obstruction

### Introduction

Hepatic hemangiomas are congenital vascular malformations and the most common benign tumors arising in the liver, with an estimated prevalence of 0.4% to 7.3% in the general population<sup>1,2</sup>. Most

hepatic hemangiomas are asymptomatic, but some (especially large lesions) cause various complications. We describe a patient with extrahepatic portal venous obstruction due to a giant hepatic hemangioma associated with Kasabach-Merritt syndrome.

---

Correspondence to Hiroshi Yoshida, MD, Department of Surgery, Nippon Medical School Tama Nagayama Hospital, 1-7-1 Nagayama, Tama, Tokyo 206-8512, Japan  
E-mail: [hiroshiy@nms.ac.jp](mailto:hiroshiy@nms.ac.jp)  
Journal Website (<http://www.nms.ac.jp/jnms/>)




Fig. 1 A computed tomographic (CT) scan, showing homogenous low-density areas, 15 cm in diameter, in the left lobe.

### Case Report

A 67-year-old woman presented with upper abdominal distension and appetite loss. The medical history was not relevant to the current disorder. Initial laboratory tests revealed the following: serum aspartate aminotransferase, 37 IU/L (normal, <28 IU/L); serum alanine aminotransferase, 40 IU/L (normal, <33 IU/L); serum alkaline phosphatase, 415 IU/L (normal 66 to 220 IU/L); serum lactic dehydrogenase, 230 IU/L (normal, 180 to 460 IU/L); serum gamma glutamic transpeptidase, 151 IU/L (normal, 8 to 39 IU/L); serum C-reactive protein, 0.10 mg/dL (normal, <0.3 mg/dL); white blood cell count, 4,500 / $\mu$ L (normal, 4,000 to 8,000 / $\mu$ L); red blood cell count,  $407 \times 10^4$  / $\mu$ L (normal, 410 to  $550 \times 10^4$  / $\mu$ L); serum hemoglobin concentration, 12.7 g/dL (normal, 14 to 18 g/dL); serum platelet count,  $9.9 \times 10^4$  / $\mu$ L (normal, 20 to  $40 \times 10^4$  / $\mu$ L); serum fibrinogen degradation products, 12  $\mu$ g/mL (normal, <10  $\mu$ g/mL); prothrombin time (international normalized ratio), 1.26 (normal, 0.70 to 1.13); and serum fibrinogen, 111 mg/dL (normal, 170 to 410 mg/dL). The serum concentration of carcinoembryonic antigen was 1.0 ng/mL (normal <2.5 ng/mL), and that of CA 19-9 was 1.0 U/mL (normal <37). Computed tomography (CT) demonstrated homogenous low-density areas, 15 cm in diameter, in the left lobe of the liver (**Fig. 1**). Drip infusion cholangiographic CT showed that the intrahepatic bile duct was compressed by the tumor (**Fig. 2**). Common hepatic arteriography revealed a



Fig. 2 A drip infusion cholangiographic CT scan, revealing compression of the intrahepatic bile duct by the tumor.

hypervascular tumor with pooling of contrast medium in the delayed phase. The portal venous phase of supramesenteric arteriography revealed obstruction and cavernous transformation of the portal vein (**Fig. 3**). We diagnosed extrahepatic portal venous obstruction due to a giant hepatic hemangioma associated with Kasabach-Merritt syndrome.

Laparotomy was performed, and the liver was found to be markedly enlarged. Dissection of the hilar structures at the mid-hilum was not performed to avoid injuring the cavernous transformation of the portal vein. Intraoperative ultrasound was done to determine the exact cutting line. After mobilization of the left lobe, left hepatectomy was performed with intermittent clamping (Pringle maneuver)<sup>3</sup>. After resection, Doppler




Fig. 3 Common hepatic arteriography revealed a hypervascular tumor with pooling of contrast medium in the delayed phase (a). The portal venous phase of supramesenteric arteriography revealed obstruction and cavernous transformation of the portal vein (b).

ultrasonography revealed recovery of the portal venous flow. The cavernous transformation shrank. Biliary leakage tests using an injection of saline and air were performed, and several leakage points were repaired with fine sutures. Hemostasis of the cut surface of the liver was achieved by ligation and the application of a fibrin glue spray (Bolheal; Chemo-Sero Therapeutic Research Institute, Kumamoto, Japan). The greater omentum was fixed to the peritoneum to prevent delayed gastric emptying<sup>45</sup>. An external drainage catheter (19 Fr. BLAKE Silicon Drain; Ethicon, Somerville, NJ, USA) was positioned in the space created by surgery. The weight of the resected specimen was 801 g.

Pathological examination of the surgical specimen confirmed the presence of a giant benign hepatic cavernous hemangioma. After operation, minor biliary leakage and right pleural effusion occurred. The biliary leakage decreased, and the patient recovered after drainage of the pleural effusion. The patient was discharged 16 days after operation. Laboratory data and complications improved after 2 months.

### Discussion

Hemangiomas are the most common primary liver tumor. The size of most hepatic hemangiomas remains stable<sup>6,7</sup>. A giant hemangioma, defined as a hemangioma exceeding 4 cm in diameter, can cause

symptoms and require treatment<sup>8</sup>. Complications of hemangiomas include congestion, bleeding, thrombosis, infarction, Kasabach-Merritt syndrome, spontaneous rupture, obstructive jaundice, and gastric outlet obstruction<sup>8-13</sup>.

Many cases of Kasabach-Merritt syndrome have been described, mostly in infants with cutaneous hemangiomas. Rarely, hepatic hemangiomas associated with Kasabach-Merritt syndrome and diffuse intravascular coagulopathy have been described. The primary pathophysiologic event of Kasabach-Merritt syndrome is platelet trapping by clotting and fibrinolysis within a vascular lesion<sup>14</sup>. The lesion may be acute and massive or chronic and low grade. More rarely, portal venous obstruction can be caused by a giant hepatic hemangioma<sup>15</sup>. In our patient, cavernous transformation of the portal vein was caused by extrahepatic portal venous obstruction by a giant hemangioma, 15 cm in diameter, associated with Kasabach-Merritt syndrome.

Various treatments are available for portal hypertension<sup>16-20</sup>. Because the portal vein was occluded by the tumor in our patient, portal hypertension improved after hepatic resection. Thrombocytopenia can be caused by hypersplenism due to portal hypertension, as well as by clotting and fibrinolysis within vascular lesions such as hemangiomas.

Because a high risk of bleeding is a primary cause

of death in Kasabach-Merritt syndrome, aggressive management is required. Symptomatic giant hemangiomas require some form of treatment, such as interferon, radiation, arterial embolization, surgical resection, and liver transplantation. However, long-term outcomes are disappointing for treatments other than liver transplantation or resection. Recent interest has focused on surgical therapy, which has produced excellent results<sup>10,12,21-27</sup>. In our patient, the laboratory data improved after operation. Surgical resection was considered an effective treatment.

### References

- Ochsner JL, Halpert B: Cavernous hemangioma of the liver. *Surgery* 1958; 43: 577-582.
- Ishak KG, Rabin L: Benign tumors of the liver. *Med Clin North Am* 1975; 59: 995-1013.
- Pringle JH: V. Notes on the Arrest of Hepatic Hemorrhage Due to Trauma. *Ann Surg* 1908; 48: 541-549.
- Yoshida H, Mamada Y, Taniai N, et al: Fixation of the greater omentum for prevention of delayed gastric emptying after left hepatectomy with lymphadenectomy for cholangiocarcinoma. *J Hepatobiliary Pancreat Surg* 2007; 14: 392-396.
- Yoshida H, Mamada Y, Taniai N, et al: Fixation of the greater omentum for prevention of delayed gastric emptying after left-sided hepatectomy: a randomized controlled trial. *Hepatogastroenterology* 2005; 52: 1334-1337.
- Weimann A, Ringe B, Klempnauer J, et al: Benign liver tumors: differential diagnosis and indications for surgery. *World J Surg* 1997; 21: 983-990; discussion 90-91.
- Yamagata M, Kanematsu T, Matsumata T, Utsunomiya T, Ikeda Y, Sugimachi K: Management of haemangioma of the liver: comparison of results between surgery and observation. *Br J Surg* 1991; 78: 1223-1225.
- Adam YG, Huvos AG, Fortner JG: Giant hemangiomas of the liver. *Ann Surg* 1970; 172: 239-245.
- Srivastava DN, Gandhi D, Seith A, Pande GK, Sahni P: Transcatheter arterial embolization in the treatment of symptomatic cavernous hemangiomas of the liver: a prospective study. *Abdom Imaging* 2001; 26: 510-514.
- Herman P, Costa ML, Machado MA, et al: Management of hepatic hemangiomas: a 14-year experience. *J Gastrointest Surg* 2005; 9: 853-859.
- Farges O, Daradkeh S, Bismuth H: Cavernous hemangiomas of the liver: are there any indications for resection? *World J Surg* 1995; 19: 19-24.
- Belli L, De Carlis L, Beati C, Rondinara G, Sansalone V, Brambilla G: Surgical treatment of symptomatic giant hemangiomas of the liver. *Surg Gynecol Obstet* 1992; 174: 474-478.
- Iwatsuki S, Todo S, Starzl TE: Excisional therapy for benign hepatic lesions. *Surg Gynecol Obstet* 1990; 171: 240-246.
- Klompmaaker IJ, Sloof MJ, van der Meer J, de Jong GM, de Bruijn KM, Bams JL: Orthotopic liver transplantation in a patient with a giant cavernous hemangioma of the liver and Kasabach-Merritt syndrome. *Transplantation* 1989; 48: 149-151.
- Takahashi T, Katoh H, Dohke M, Okushiba S: A giant hepatic hemangioma with secondary portal hypertension: a case report of successful surgical treatment. *Hepatogastroenterology* 1997; 44: 1212-1214.
- Yoshida H, Mamada Y, Taniai N, Tajiri T: New methods for the management of gastric varices. *World J Gastroenterol* 2006; 12: 5926-5931.
- Yoshida H, Mamada Y, Taniai N, Tajiri T: New methods for the management of esophageal varices. *World J Gastroenterol* 2007; 13: 1641-1645.
- Yoshida H, Mamada Y, Taniai N, Tajiri T: Partial splenic embolization. *Hepatol Res* 2008; 38: 225-233.
- Yoshida H, Mamada Y, Taniai N, Tajiri T: New trends in surgical treatment for portal hypertension. *Hepatol Res* 2009; 39: 1044-1051.
- Yoshida H, Mamada Y, Taniai N, et al: A randomized control trial of bi-monthly versus bi-weekly endoscopic variceal ligation of esophageal varices. *Am J Gastroenterol* 2005; 100: 2005-2009.
- Starzl TE, Koep LJ, Weil R 3rd, et al: Excisional treatment of cavernous hemangioma of the liver. *Ann Surg* 1980; 192: 25-27.
- Schwartz SI, Husser WC: Cavernous hemangioma of the liver. A single institution report of 16 resections. *Ann Surg* 1987; 205: 456-465.
- Kuo PC, Lewis WD, Jenkins RL: Treatment of giant hemangiomas of the liver by enucleation. *J Am Coll Surg* 1994; 178: 49-53.
- Borgonovo G, Razzetta F, Arezzo A, Torre G, Mattioli F: Giant hemangiomas of the liver: surgical treatment by liver resection. *Hepatogastroenterology* 1997; 44: 231-234.
- Pietrabissa A, Giulianotti P, Campatelli A, et al: Management and follow-up of 78 giant haemangiomas of the liver. *Br J Surg* 1996; 83: 915-918.
- Brouwers MA, Peeters PM, de Jong KP, et al: Surgical treatment of giant haemangioma of the liver. *Br J Surg* 1997; 84: 314-316.
- Ozden I, Emre A, Alper A, et al: Long-term results of surgery for liver hemangiomas. *Arch Surg* 2000; 135: 978-981.

(Received, July 13, 2010)

(Accepted, August 4, 2010)